Modifying the Disease Course
More than a dozen disease modifying therapies are approved by the U.S. Food and Drug Administration (FDA) for use in relapsing forms of MS. This includes individuals who have active secondary-progressive MS, meaning they continue to have inflammatory demyelination (new lesions on MRI) and clinical relapses. Individuals who have been on one of these medications during the initial relapsing-remitting phase of the disease will likely continue on it unless it is no longer adequately controlling their disease activity.
Mavenclad®, an oral therapy, is FDA approved for relapsing forms of MS including active secondary progressive MS.
Mayzent®, an oral therapy, is FDA approved for relapsing forms of MS including active secondary progressive MS.
Novantrone® is FDA-approved for people with worsening relapsing-remitting MS (worsening in between relapses) and those with secondary progressive MS (started with relapses but are now worsening with no or few relapses). This DMT is used infrequently due to serious side effects and risks.
Read more about these therapies in The MS Disease-Modifying Medications (.pdf).
Read more about starting, stopping or switching medications in the American Academy of Neurology Guideline: Disease Modifying Therapies for Adults with Multiple Sclerosis.